CWP
TEVA icon

Capital Wealth Planning’s Teva Pharmaceuticals TEVA Stock Holding History

Capital Wealth Planning’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-20,000
Closed -$1K – 238
2019
Q3 		$1K Sell
20,000
-5,000
-20% -$38.3K ﹤0.01% 262
2019
Q2 		$6K Buy
+25,000
New +$301K ﹤0.01% 258

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Capital Wealth Planning's TEVA Position: Q2 2026 in Review

Capital Wealth Planning increased its Teva Pharmaceuticals (TEVA) stake by 54% in Q2 2026, buying an estimated $9.38M and bringing the position to 806,742 shares worth $27.3M. The position accounts for 0.14% of the portfolio, ranked #56.

Capital Wealth Planning first reported a position in TEVA in Q2 2019 and has held it in 14 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Capital Wealth Planning held 806,742 shares of Teva Pharmaceuticals worth $27.3M as of Q2 2026.
  • Capital Wealth Planning bought 281,742 Teva Pharmaceuticals shares in Q2 2026, an estimated $9.38M.
  • Teva Pharmaceuticals made up 0.14% of Capital Wealth Planning's portfolio in Q2 2026, its #56 holding.
  • Capital Wealth Planning first reported a position in Teva Pharmaceuticals in Q2 2019 and has held it in 14 quarters since.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Capital Wealth Planning's 13F filing for Q2 2026, filed 14 Aug 2026.